Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Lidocaine Ointment USP, 5%, the generic version of Xylocaine Ointment, 5% of AstraZeneca.

According to IMS Health sales data for the 12 month period ending July 2016, the Xylocaine Ointment, 5% market achieved annual sales of approximately $373.0 million.

Also read: Global coalition CEPI formed to tackle infectious diseases

Glenmark's current portfolio consists of 109 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the U.S. FDA.